AU2017342273B2 - TCRa homing endonuclease variants - Google Patents

TCRa homing endonuclease variants Download PDF

Info

Publication number
AU2017342273B2
AU2017342273B2 AU2017342273A AU2017342273A AU2017342273B2 AU 2017342273 B2 AU2017342273 B2 AU 2017342273B2 AU 2017342273 A AU2017342273 A AU 2017342273A AU 2017342273 A AU2017342273 A AU 2017342273A AU 2017342273 B2 AU2017342273 B2 AU 2017342273B2
Authority
AU
Australia
Prior art keywords
leu
lys
gly
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017342273A
Other languages
English (en)
Other versions
AU2017342273A1 (en
Inventor
Jordan JARJOUR
Mark POGSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017342273A1 publication Critical patent/AU2017342273A1/en
Assigned to 2SEVENTY BIO, INC. reassignment 2SEVENTY BIO, INC. Request for Assignment Assignors: BLUEBIRD BIO, INC.
Application granted granted Critical
Publication of AU2017342273B2 publication Critical patent/AU2017342273B2/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. Request for Assignment Assignors: 2SEVENTY BIO, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
    • C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Television Signal Processing For Recording (AREA)
  • Treating Waste Gases (AREA)
  • Peptides Or Proteins (AREA)
AU2017342273A 2016-10-11 2017-10-11 TCRa homing endonuclease variants Active AU2017342273B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662406689P 2016-10-11 2016-10-11
US62/406,689 2016-10-11
US201662414266P 2016-10-28 2016-10-28
US62/414,266 2016-10-28
PCT/US2017/056178 WO2018071565A1 (en) 2016-10-11 2017-10-11 TCRa HOMING ENDONUCLEASE VARIANTS

Publications (2)

Publication Number Publication Date
AU2017342273A1 AU2017342273A1 (en) 2019-05-09
AU2017342273B2 true AU2017342273B2 (en) 2023-07-06

Family

ID=61905974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017342273A Active AU2017342273B2 (en) 2016-10-11 2017-10-11 TCRa homing endonuclease variants

Country Status (13)

Country Link
US (2) US11591582B2 (enExample)
EP (1) EP3534916A4 (enExample)
JP (1) JP7104710B2 (enExample)
KR (1) KR20190065382A (enExample)
CN (1) CN110036107B (enExample)
AU (1) AU2017342273B2 (enExample)
CA (1) CA3039812A1 (enExample)
IL (1) IL265895A (enExample)
MA (1) MA46717A (enExample)
MX (1) MX2019004156A (enExample)
RU (1) RU2019114035A (enExample)
SG (1) SG11201903230QA (enExample)
WO (1) WO2018071565A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102622910B1 (ko) 2016-09-08 2024-01-10 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
US11591582B2 (en) 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants
WO2018075541A1 (en) 2016-10-17 2018-04-26 Bluebird Bio, Inc. TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
KR20210102925A (ko) 2018-12-10 2021-08-20 블루버드 바이오, 인코포레이티드. 호밍 엔도뉴클레아제 변이체
US20240336904A1 (en) * 2020-12-21 2024-10-10 2Seventy Bio, Inc. Compositions and methods for site-directed mutagenesis
WO2022266038A1 (en) 2021-06-14 2022-12-22 2Seventy Bio, Inc. Single stranded rna purification methods
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140208457A1 (en) * 2011-06-10 2014-07-24 Basf Plant Science Company Gmbh Nuclease Fusion Protein and Uses Thereof
WO2014191527A1 (en) * 2013-05-31 2014-12-04 Cellectis A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
DE60203125T2 (de) * 2001-08-31 2006-04-06 Avidex Ltd., Abingdon Löslicher t zell rezeptor
KR100415267B1 (ko) * 2002-02-19 2004-01-16 오광수 2단 발효법에 의한 고 순도 멸치액젓 및 그 제조방법
EP1413626A1 (en) * 2002-10-23 2004-04-28 Vicuron Pharmaceuticals, Inc. Genes and proteins for the biosynthesis of the glycopeptide antibiotic A40926
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20140148361A1 (en) 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof
US9034813B2 (en) * 2010-09-17 2015-05-19 Ecolab Usa Inc. High performance low viscoelasticity foaming detergent compositions employing extended chain anionic surfactants
US8450107B1 (en) * 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
CN111676196A (zh) * 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
US11591582B2 (en) 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140208457A1 (en) * 2011-06-10 2014-07-24 Basf Plant Science Company Gmbh Nuclease Fusion Protein and Uses Thereof
WO2014191527A1 (en) * 2013-05-31 2014-12-04 Cellectis A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof
US20160130569A1 (en) * 2013-05-31 2016-05-12 Cellectis A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
French et al., What is Conservative Substitution?, Journal Molecular Evolution, 1983, v 19, p171-175 *

Also Published As

Publication number Publication date
WO2018071565A1 (en) 2018-04-19
AU2017342273A1 (en) 2019-05-09
US20220186198A1 (en) 2022-06-16
MX2019004156A (es) 2019-09-26
US11591582B2 (en) 2023-02-28
SG11201903230QA (en) 2019-05-30
US12264343B2 (en) 2025-04-01
RU2019114035A (ru) 2020-11-13
JP2019532674A (ja) 2019-11-14
CN110036107B (zh) 2024-12-27
KR20190065382A (ko) 2019-06-11
CN110036107A (zh) 2019-07-19
US20230357736A1 (en) 2023-11-09
JP7104710B2 (ja) 2022-07-21
CA3039812A1 (en) 2018-04-19
EP3534916A4 (en) 2020-09-30
EP3534916A1 (en) 2019-09-11
IL265895A (en) 2019-06-30
MA46717A (fr) 2019-09-11

Similar Documents

Publication Publication Date Title
US12264343B2 (en) TCRa homing endonuclease variants
US11732255B2 (en) CBLB endonuclease variants, compositions, and methods of use
EP3510157B1 (en) Pd-1 homing endonuclease variants, compositions, and methods of use
US20250327049A1 (en) Cblb endonuclease variants, compositions, and methods of use
US20190184035A1 (en) Bcl11a homing endonuclease variants, compositions, and methods of use
US20190309274A1 (en) Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
AU2018221730A1 (en) Donor repair templates multiplex genome editing
US20200123515A1 (en) TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
US20220064651A1 (en) Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
WO2019126558A1 (en) Ahr homing endonuclease variants, compositions, and methods of use
US20220364123A1 (en) Wiskott-aldrich syndrome gene homing endonuclease variants, compositions, and methods of use
CA3122278A1 (en) Homing endonuclease variants
US20210230565A1 (en) Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: 2SEVENTY BIO, INC.

Free format text: FORMER APPLICANT(S): BLUEBIRD BIO, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: REGENERON PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): 2SEVENTY BIO, INC.